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Effects of acute and chronic angiotensin converting enzyme 
inhibition by spirapril on cardiovascular regulation in 
essential hypertensive patients. Assessment by spectral 
analysis and haemodynamic measurements
DERK. P. VEERMAN, CAROLINE E. DOUMA, MARIE-CECILE JACOBS, THEO THIEN & 
GERT A. VAN M ONTFRANS
1 The effects of a first dose and of chronic treatment with spirapril, a novel 
angiotensin converting enzyme (ACE) inhibitor, on short-term blood pressure 
and heart rate fluctuations were assessed by fast Fourier spectral analysis. The 
effects on systemic haemodynamics in supine and standing position were also 
studied. We treated 11 patients with 3 mg and 13 patients with 12 mg spirapril 
for 8 weeks.
2 Overall blood pressure variability was not changed by spirapril. By spectral 
analysis the changes in blood pressure and heart rate variability in various 
frequency bands can be assessed, which may be related to changes in activity 
of the autonomic nervous system. The relative power in the mid-frequency 
band (0.08-0.12 Hz) of supine systolic pressure was 23 + 10% during placebo 
and decreased during treatment with 12mg to 11+4%  (P<0.01 vs placebo, 
first dose) and to 13 ±6%  (P<0.01, chronic treatment). Standing systolic mid- 
frequency power was 38 +  12% during placebo and decreased to 27 + 9% 
(PcO.Ol vs placebo) after the first dose of 12 mg, but it did not decrease after 
chronic treatment (29 ±  13%). Treatment with 3 mg induced no changes in 
mid-frequency blood pressure variability. A decrease in power of the 
mid-frequency band may point to a decrease in sympathetic vascular drive.
The power in the high-frequency band (0.15-0.40 Hz) of heart rate did not
change after treatment, suggesting that there is no change in the vagal 
cardiac drive.
3 Supine blood pressure decreased by a decrease in vascular resistance by
(3 mg) and 14±19% (12 mg) after 8 weeks treatment. Heart rate, 
stroke volume and cardiac output did not change. No orthostatic hypotension 
occurred after the first dose. In the 12 mg group the orthostatic induced rise in 
heart rate (compared with supine) increased from + 9 ± 5  beats min“1 (placebo)
to + 1 4 ± 4  beats m in“"1 ( P <0.05) after the first dose. No changes in the 
orthostatic heart rate increase occurred in the 3 mg group. The orthostatic 
changes in stroke volume, cardiac output and vascular resistance were not
influenced by spirapril.
4 In conclusion, the decrease in mid-frequency blood pressure variability may 
suggest an inhibitory effect of acute and chronic ACE inhibition upon 
sympathetic vasomotor control. Vagal activity was not influenced as high- 
frequency heart rate variability did not change. Acute and chronic ACE
inhibition did not blunt important cardiovascular reflexes, as the haemodynamic
response to orthostasis remained
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Introduction dosages (3 and 12 mg once daily) of spirapril on 24 h
ambulatory blood pressure was studied in patients with 
Angiotensin converting enzyme (ACE) inhibitors are an mild to moderate essential hypertension [15]. All 
important class of drugs for the treatment of essential patients who participated in that study from our 
hypertension and congestive heart failure [1,2]. institutions also took part in the present study.
Although extensive investigations on their mechanisms The study group comprised 30 patients, aged between
of action have been performed, there are still some 20 and 60 years, all having essential hypertension. The
unresolved questions. By inhibiting the angiotensin sitting diastolic blood pressure (Korotkoff phase V) of
converting enzyme levels they decrease the levels of all patients was between 100 and 120mmHg (average
circulating angiotensin II and aldosterone [1,2], thereby of three office readings) after a period of 4 weeks placebo
inhibiting vasoconstriction and salt and water treatment. Secondary hypertension and overt target
retention. ACE inhibitors also exert an influence on the organ damage were excluded by physical examination,
autonomic nervous system [3,4] which may contribute routine laboratory investigations, ECG and chest
to their blood pressure lowering effect and could explain X-ray. All antihypertensive and other medications which
the absence of reflex tachycardia. However, there is a might influence the cardiovascular system were discon-
vast body of conflicting data whether ACE inhibition tinued at the start of the placebo phase of the study,
enhances parasympathetic activity without a concomi- Patients were instructed to refrain from changing their
tant influence on sympathetic activity [5,6], or whether usual diet and level of physical activity and also to
sympathetic activity is diminished by ACE inhibition abstain from using NSAIDs for the duration of the study.
[7 -9 ]. An alternative explanation for the absence of Basic characteristics of all patients are listed in Table 1.
reflex tachycardia may be that ACE inhibitors increase No patients showed signs of left ventricular hypertrophy
venous compliance, thereby reducing preload [1,10]. on the ECG. The protocol was drafted in accordance
The aim of this study was to examine the effects of with the declaration of Helsinki (1989), approved by
ACE inhibition on autonomic nervous function by the local hospital ethics committees and all subjects
studying heart rate variations during forced breathing gave written informed consent.
(which is a measure of vagal tone) and by studying 
blood pressure and heart rate variations by spectral
analysis. Spectral analysis breaks down a signal to Study design 
its constituent frequency components, and quantifies
the power of these components. Modulation of blood The complete duration of the study was 12 weeks: 4
pressure and heart rate by baroreflex and sympathetic weeks placebo treatment was followed by an active
and parasympathetic nervous activity has been shown treatment phase of 8 weeks during which patients were
to be involved in the genesis of the various frequency treated with either 3 or 12 mg of spirapril in a double-
components of blood pressure and heart rate variability blind randomized fashion. Patients were instructed to
[11]. We also studied the haemodynamic changes upon take one identical capsule every morning before break-
standing during ACE as these changes are fast at the same time.
largely influenced by adjustments in vagal and sympath- During the study three measurement cycles were
etic activity [12]. As ACE inhibitors can occasionally performed. The first after 4 weeks placebo treatment 
cause a pronounced drop in blood pressure after a first (baseline). The second measurement cycle was performed 
dose [13,14] we examined the effects of both acute (first
dose) and chronic treatment. We studied these effects in 
patients with essential mild to moderate hypertension 
by using the ACE inhibitor spirapril (TÏ 211-950, 
Sandoz, Basel, Switzerland) which is a new non-
Table 1 Basic characteristics. Patients received 3 or 12 mg 
of spirapril. Blood pressure is clinic cuff pressure after 4 
weeks placebo treatment, average of three readings in the 
sitting position. Results are expressed as mean±s.d. No
sulphhydryl ACE inhibitor. Spirapril itself is inactive, significant differences existed between the two groups 
but is rapidly de-esterified after absorption to its active
diacid metabolite spiraprilat. Spirapril has been shown
to be a potent blood pressure lowering agent with a
long duration of action [15].
Methods
This study was part of a larger multicentre study (4 
centres) in which the efficacy and tolerability of two
3 mg(n =11) 12 mg ( n =  13 )
Age (years) 48 ± 5 46 ± 9
Weight (kg) 83 ±  17 83 ±13
Height (cm) 171 ± 8 172 ± 8
M /F 7/4 9/4
Heart rate (beats min-1 ) 66+11 67+ 12
Clinic cuff pressure
(mmHg)
Systolic 159 ±  15 162±16
Diastolic 106 ± 3 107 +  5
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4 h after the first active medication was taken, which calculated the power in two frequency bands: the mid-
was ingested immediately after the first measurement frequency band (0.08-0.12 Hz) and the high-frequency
cycle (acute treatment, first dose). The third and also band (0.15-0.40 Hz). The power of these frequency bands
last measurement cycle was performed after 8 weeks is considered to reflect sympathetic and vagal activity
active treatment, again 4 h  after ingestion of the active respectively [11,20-22]. Total variance and percentual
medication (chronic treatment). Blood samples were variance (power) of the mid-frequency and high-frequency
taken on both measurement days prior to and 4 h after band of blood pressure and pulse interval in supine and
ingestion of the medication for determination of plasma standing position were determined for the three different
ACE concentrations by a colour kinetic assay. measurement cycles: the placebo phase (P), after the first 
dose (A) and after chronic treatment (C).
Measurements
Beat-to-beat noninvasive finger
amics The signal analysis program a  
the beat-to-beat values of left ventricular stroke 
pressure was (SV), cardiac output (CO) and total peripheral resistance
recorded by Finapres during all three above mentioned (TPR) using the pulse contour algorithm of Wesseling
measurement cycles [16-18]. Every measurement cycle [23]. In short, SY is calculated from the aortic
started with a test for forced respiratory sinus arrhythmia characteristic impedance and the arterial pressure wave-
(FRSA) during which the patient was requested to form as the integral of the pressure pulse over the
perform six maximal inspirations and expirations con- arterial systolic period [24,25], On comparison of CO
secutively for 60 s. Thereafter the patient remained in by this method with thermodilution during changes in
the supine position for 10 min. The patient was then blood pressure and heart rate in open heart surgery, a
asked to stand up within 2 to 3 s and remain standing standard deviation of the difference between the two
quietly for 5 min. A marker pulse identified the onset of methods of 10.6% (=0.541 min-1) was found [25]. To
the inspirations during FRSA, as well as the onset of obtain absolute SV values, calibration with a standard
the supine and standing periods. Care was taken to method such as thermodilution is needed, but without
keep the hand, on which the finger blood pressure was such calibration the relative changes in SY can be used
measured, at heart level (4th intercostal space in the [23,24]. When comparing the pulse contour algorithm
midaxillar line) during the complete measurement cycle applied to finger and intrabrachial arterial pressure
to avoid hydrostatic errors. Finger blood pressure was waveforms [12], we obtained almost identical results.
measured at the same finger at all times. We determined the absolute changes in mean arterial
The manoeuvres were performed in the morning in a pressure (MAP) and heart rate (HR) and the relative
room with a constant temperature of 22-24° C. All changes in SV, CO and TPR induced by acute and
subjects abstained from coffee, tea and smoking starting chronic ACE inhibition after 10 min in
the evening before the experiments. The continuous position compared with the placebo phase. Also, the
blood pressure recording and the m arker pulse signal absolute and relative changes in
were on line analogue-to-digital converted by a personal induced by standing were assessed. The values of all
computer at 100 Hz per signal. during the last minute of the supine position
before up and the minute of
Data analysis
standing were averaged for all individual patients. We
determined induced by in
By means of a signal analysis program the time of the 
systolic upstroke was identified for each beat, as were 
the actual systolic, mean and diastolic pressures and the 
interbeat interval (resolution 10 ms). The registration Statistics  
of six patients was not suitable for 
technical reasons. Of the remaining
placebo period, after the first dose and after 8 weeks
to
11 Statistical t \ L* Biomedical 
\sity ofpatients were treated with 3 mg and 13 patients with Programs (BMDP) statistical software 
12 mg of spirapril. California, Los Angeles, CA, USA). Results are
as mean ±  s.d. A Kruskall-Wallis one-way analysis of 
F R S A  The largest of the six differences between variance by ranks was used to compare dosage groups
inspiration and expiration (I/E) in pulse interval were and the effect of acute and chronic treatment
determined for each patient during baseline, acute and followed in case of
chronic treatment [19]. U -test or a Wilcoxon 
data. A P<0.05 was
by a Mann 
rank test in case
;ant.
Power spectra Power spectra were estimated by means 
of fast Fourier transformation [11,20,21] of supine and 
standing blood pressure and heart rate. The first minute 
of standing was omitted from the analysis as stabilization Results 
of blood pressure and heart rate takes some time.
Integration of the curve for specific frequency-bands Haemodynamic changes induced by ACE inhibition are 
yields variance for that particular frequency band. We summarized in Table 2. Spirapril caused a reduction in
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Table 2 Haemodynamic changes. Haemodynamic changes 
at rest induced by spirapril 4 h after the first dose (acute) and 
after 8 weeks treatment (chronic) compared to the placebo 
phase. The changes in mean arterial pressure (MAP) and 
heart rate (HR) and the relative changes in stroke volume 
(SY), cardiac output (CO) and total peripheral resistance 
(TPR) were determined after 10 min in the supine position. 
Results are mean±s.d.; *jP < 0.05 compared to placebo, 
Wilcoxon signed rank test.
3 mg ( n = l l ) 12 mg (n= 13)
Acute Chronic Acute Chronic
A MAP (mmHg) —10 +  7* - 9  ±11* — 8 ±6* - 1 3 + 8 *
A HR (beats —1 +  10 —  1 ±  11 +1 ±  6 —1 ± 7
min “1 )
ASV (%) + 14  +  24 +12 dt 23 — 1 ±21 +  7 ±26
ACO (%) +11 +  28 * « H w n - 1 3  +  31 +  3 ±  26 +  8 ±30
ATPR (%) — 14 ± 22 - 1 6  +  23* — 6 ±20 —14±19*
blood pressure in both dosage groups, which was already 
significant after the first dose. Mean supine (Finapres) 
arterial pressure in the placebo phase was 101 ±  9 mmHg 
in the 3 mg and 101 ±15 mmHg in the 12 mg group. 
Compared with placebo vascular resistance did not 
decrease significantly after the first dose, but during 
chronic treatment it decreased by 16 ±23%  (Pc0.05) in 
the 3 mg group and by 14±19% (Pc0.05) in the 12 mg
group. The changes in heart rate, stroke volume and 
cardiac output after treatment with spirapril were not 
significant. Compared with the placebo phase plasma 
ACE decreased from 12.5+1.2 mu I“ 1 to 2.9 +1.1 mu I-1WNIWN MMm
(PcO.Ol) in the 3 mg and from 14.3 ±3.0 mu I-1 to 
2.2±4.0 n u ll-1 (PcO.Ol) in the 12mg group after the 
first dose. Pre-dose ACE concentrations after 8 weeks 
treatment were 10.5±3.4 mu I""1 (3 mg, P>0.05 vs 
placebo) and 7.2±2.8 mu I-1 (12 mg, P<0.05 vs 
placebo). ACE levels 4 h  post-dose were 3.2±1.1 m u l“ 1 
(3 mg, PcO.Ol vs placebo) and 1.4±6.0 m u l-1 (12 mg, 
P<0.01 vs placebo). The decrease in plasma ACE 
concentrations did not differ between the 3 and 12 mg 
groups, except for the pre-dose ACE concentration after 
8 weeks treatment. This ACE level was significantly lower 
in the 12 mg group than in the 3 mg group (Pc0.05).
F R SA
Group averaged 1-E difference in the 3 mg group did 
not show any significant difference when the placebo 
phase (I-E  difference 230 ±72  ms) was compared with 
the acute (272 ±69 ms) or chronic (205 +  86 ms) treat­
ment phase. Also the I-E  difference of the 12 mg group 
did not differ between the placebo phase (229 ±86 ms) 
and the acute (226 + 93 ms) and chronic (268 ±93 ms)
treatment phase.
Spectral analysis
Treatment with spirapril did not change overall 
variability of systolic blood pressure, both in the
3 mg group (supine variance: P : 79 ±  52; A : 92 ±  63; 
C :7 3 ± 3 6 mmHg2, standing variance: P :5 8 ± 3 3 ; A: 
79±42; C: 88 ±25 mmHg2) and the 12 mg group 
(supine variance: P : 54 ±  32; A : 47 ±  21; C : 53 ±
30 mmHg2, standing variance: P : 85 ±  47; A: 71 ±43; 
C:68±37 mmHg2). There were also no differences of 
overall variability of diastolic pressure and pulse interval, 
when comparing the placebo with the treatment periods.
In the placebo period there were no differences 
between the 3 and 12 mg groups in the relative power 
of the mid-frequency and high-frequency band of either 
systolic or diastolic pressure or pulse interval. Figure 1 
shows that there were no changes in the power of the 
mid-frequency band after treatment with 3 mg 
spirapril. After the first dose of 12 mg spirapril, percen- 
tual power of the mid-frequency band decreased both in 
supine (from 23±  10 to 11 ±4% ; PcO.Ol) and in 
standing position (from 38±  12 to 27±9% ; PcO.Ol). 
Mid-frequency power of systolic pressure decreased 
during chronic treatment with 12 mg of spirapril in 
supine position (13± 6% , PcO.Ol) but not in standing 
position (29 +  13%, P>0.05). Power in the mid­
frequency band of diastolic pressure or pulse interval 
did not change in the 12 mg group. Power of the high- 
frequency band of pulse interval did not change after 
treatment with spirapril, either in supine or standing 
position, in the 3 or 12 mg group (Figure 1).
Orthostatic haemodynamics
The haemodynamic changes upon standing are summar­
ized in Figure 2. Standing from supine induced an 
increase in HR and MAP. In the 12 mg group the 
increase in HR after the first dose, but not after chronic 
treatment, was significantly larger than in the placebo 
phase (placebo 9 ±5; first dose 14±4, Pc0 .05 ; chronic 
treatment 12±6  beats m in "1, P>0.05). Increase in HR 
after standing in the 3 mg group was not different from 
the placebo phase. MAP also increased after standing 
from supine, treatment with either 3 or 12 mg spirapril 
did not change the magnitude of this increase both after 
the first dose or after 8 weeks treatment.
SV and CO generally decrease upon standing from 
supine. The increment in total peripheral resistance 
upon standing, proportionally larger than the decrease 
in CO, causes a rise in mean blood pressure. Acute or 
chronic treatment with spirapril did not influence the 
magnitude of the changes in SV, CO and TPR upon 
standing.
Discussion
The present analysis showed no difference in the blood 
pressure lowering effects of 3 and 12 mg spirapril 
(Table 2) or in the decrease of plasma ACE levels. Blood 
pressure was decreased by a decrease in total peripheral 
resistance (Table 2). Despite the spirapril induced vaso­
dilation, we found no reflex increase in stroke volume, 
cardiac output or heart rate. The haemodynamic profile
© 1996 Blackwell Science Ltd British Journal of Clinical Pharmacology 41, 49-56
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Figure 1 Percentual powers of the mid-frequency band (MF: 0.08-0.12 Hz) and the high-frequency band (HF: 0.15-0.40 Hz) of 
systolic (PS) and diastolic (PD) blood pressure (supine • ;  standing O) and pulse interval (INT) before (Placebo =  P), after the 
first dose, (Acute =  A) and after 8 weeks treatment (Chronic =  C) with 3 mg (n =  l l )  or 12 mg (n — 13) of the ACE inhibitor 
spirapril. Results are group averages, bars represent standard deviations. A star indicates a statistical difference vs placebo
(*P<0.01).
of spirapril thus appears to be comparable with other pressor and a decreased blood pressure fall due to 
ACE inhibitors [1], Since reflex cardio-stimulation by a-adrenergic receptor blockade after ACE inhibition,
vasodilators may favour left ventricular hypertrophy and this was to indicate a decrease in
[26], the absence of a heart rate or stroke volume sympathictonus [8]. Although angiotensin II facilitates 
increase during treatment with ACE inhibitors may be noradrenaline release from terminal nerve endings [3], 
considered as an important advantage from a clinical a number of studies reported no decrease in plasma
point of view.
Numerous papers show an effect of ACE inhibitors 
on the autonomic nervous system, and this may at least 
partly explain the absence of reflex counter-regulatory 
reactions [1,2]. However, there is no consensus whether
catecholamines during treatment with an ACE inhibitor 
[6,27,28]. However, Philipp et al. [7] demonstrated a
significant decrease in 
ACE inhibition.
I n
non during
to 0% nn/HìMk.'.f J  V Ï  tv in
this effect concerns an increased parasympathetic or a vagal and sympathetic chronic
decreased sympathetic activity or both. 
Several studies showed an increase in
induced heart rate varu [27] or an increas
ACE inhibition by studying pulse interval variability 
during forced respiration (FRSA) [19], and by studying 
the variability of blood and interval
bradycardia during the diving reflex [5,28] after admin- in the mid- high-frequency bands by spectral
istration of an ACE inhibitor. This was interpreted to analysis. Several factors influence the blood pressure
represent an increased vagal tone. However, other and pulse interval spectra. Neural
studies showed a smaller decrease in heart rate during considered to be the most important, and most of the
facial immersion in water (‘diving’) [6,29]. This last spectral components are probably generated by sym-
finding was also considered to express an increase in pathetic and parasympathetic nervous activity and the
vagal tone through ACE inhibition. Thus, opposite baroreflex [11,20-22]. Blood pressure variations which
results are supposed to be caused by the same change cause baroreflex modulation of pulse interval by para-
in vagal activity. This suggests that no consensus on 
this topic is reached in the literature.
sympathetic nerves affect both high-frequency and mid­
frequency powers, although mid-frequency power of
Changes in sympathetic nervous system activity after pulse interval is also influenced by sympathetic nervous
treatment with ACE inhibitors have also been studied activity due to the time delay of baroreflex action in the
by studying cardiovascular responses to standardized mid-frequency range [11,31]. Thus, the high-frequency 
manoeuvres. In several studies no changes in the pulse interval variability may be considered to have the 
cardiovascular reactions to handgrip, mental stress or closest relation to vagal cardiac tone. Experiments with
cold pressor have been reported [5,28-30]. Another pharmacological vagal blockade corroborate this
study reported a decreased tachycardia during cold notion [22,32],
© 1996 Blackwell Science Ltd British Journal o f Clinical Pharmacology 41, 49-56
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studying cardiovascular reflex responses is that spectral 
analysis may give an estimate of vagal and sympathetic 
activity during steady state circumstances, whilst the 
magnitude of vagally or sympathetically steered reflex 
responses may also be dependent on the unknown level 
of resting vagal or sympathetic tone.
We found no changes in the FRSA after acute and 
chronic treatment with spirapril Also, no changes in 
the power of the mid- and high-frequency band of heart 
rate were found in the present study. In the low dose 
group (3 mg) the power of the mid-frequency band of 
blood pressure did not change, but in the higher dosage 
group (12 mg) a decrease in systolic blood pressure 
variability in this frequency band was observed both 
after acute and chronic treatment with spirapril. Thus, 
no increment of vagal tone during ACE inhibition 
and no change in cardiac sympathetic tone was 
found. However, we did find a decrease of sympathetic
■
vasomotor tone during ACE inhibition in our patients 
by spectral analysis. This finding is in agreement with 
studies by Pagani et al. [37] and by Dutrey-Dupagne 
el al. [36] who also found a decrease of the mid­
frequency band of blood pressure variability after ACE 
inhibition. As discussed above plasma noradrenaline 
does not decrease, but the pressor response of the end- 
organ (peripheral blood vessels) to sympathetic stimula­
tion (noradrenaline) may be decreased after ACE 
inhibition [38,39]. Thus, a sympatho-modulating effect 
of ACE inhibitors appears to be related to an effect on 
the neurotransmission at the postjunctional site, leading 
to diminished facilitation of noradrenergic stimuli rather 
than to a direct effect on the sympathetic nervous 
system itself.
Although an increase in ‘overall’ sympathetic nervous 
activity is considered to have unfavourable effects in 
hypertension [40], the pathophysiological and clinical 
importance of sympathetic attenuation by ACE inhibi­
tors remains doubtful. Although we found a decrease in 
blood pressure and plasma ACE concentrations in the 
3 mg group we did not find an effect on the sympathetic 
nervous system in that group. Also, the increase in 
There is much discussion on the origin of the blood vascular resistance by sympathetic activation upon 
pressure variability in the 0.1 Hz frequency range. standing did not change after ACE inhibition. Moreover 
Sympathetic vasomotor activity probably plays an there is no agreement in the literature about the exact 
important role as well as the baroreflex, as shown by effect of ACE inhibitors on the autonomic nervous
A HR MAP SV CO TPR
Figure 2 Effects of ACE inhibition by spirapril on the 
haemodynamic changes induced by standing. This figure 
shows the changes in heart rate (HR), mean arterial pressure 
(MAP), stroke volume (SV), cardiac output (CO), and total 
peripheral resistance (TPR) after 5 min standing compared 
with supine. Haemodynamic changes induced by standing in
the placebo period (U) and after the first dose (■) and after
8 weeks treatment (83) with either a) 3 (n=l l )  or b) 12 (n = 
13) mg spirapril are shown. In the 12 mg group, but not in 
the 3 mg group, there is a larger increase in heart rate upon 
standing after the first dose. Changes in MAP, SV, CO and 
TPR were not different from the placebo period. *P< 0.05 vs 
placebo.
blood pressure varie around this system, notwithstanding the large number of studies.
frequency decreases after sino-aortic denervation, while Occasionally, symptomatic hypotension is seen follow-
total blood pressure variability increases (mainly by an ing a first dose of an ACE inhibitor [13,14], but in our
increase in lower frequency variability) [33], Moreover, patients the haemodynamic response to orthostasis
there are theoretical arguments for the existence of a remained intact and nobody complained about dizziness
0.1 Hz resonance phenomenon in the feedback arterial upon standing. Although ACE inhibition causes arterial
baroreceptor-sympathetic vasomotor loop [34]. Much vasodilatation, cardiac output does not increase after
simplified, mid-frequency oscillations in blood pressure treatment with these drugs [1 ], as was confirmed by
may be the result of the delayed sympathetic vasomotor our results (Table 2). This may be related to venous
reaction on blood pressure changes sensed by the dilatation caused by ACE inhibitors, forearm venous
baroreceptor and thus impose a specific rhythm on distensibility increases in response to administration of
blood pressure [11,21]. This explanation of mid- ACE inhibitors [41], In our subjects the increase in
frequency blood pressure variability is supported by heart rate upon standing was significantly larger after
fact that it is diminished by pharmacological acute ACE inhibition in the 12 mg group. This may be
a-adrenergic receptor blockade [22,32] and when related to a more pronounced gravitational pooling of
baroreflex sensitivity is decreased [35]. blood due to an increase in venous compliance
An advantage of this technique as compared with [10,42,43], although we did not find significant
© 1996 Blackwell Science Ltd British Journal of Clinical Pharmacology 41, 49-56
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differences in the decrease in stroke volume upon 
standing. An ACE inhibition-induced decrease in stroke 
volume and increase in heart rate during tilt was found 
by Ibsen et al. [44]. However, during lower body 
negative pressure the increase in heart rate did not 
change after ACE inhibition, and the decrease in forearm 
blood flow was even smaller [45,46]. Thus, although 
there is some data to support the view that ACE 
inhibition increases venous compliance, as yet the 
evidence is far from conclusive.
In conclusion, spirapril decreases blood pressure by 
decreasing total peripheral resistance, without causing 
an increase in heart rate, stroke volume or 
output. There are some indications for an inhibitory 
effect of acute and chronic ACE inhibition by spirapril 
upon sympathetic vasomotor control, while parasympa­
thetic cardiac drive was not influenced. The haemo­
dynamic response to orthostasis remained intact, and 
no clear evidence for a venodilatatory response was 
found in our subjects.
We gratefully acknowledge the support for this study by 
Sandoz AG, Switzerland and Sandoz BY, Netherlands.
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